A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease [Corrigendum]

Autor: Joseph Tauber, Barry A Schechter, Jason Bacharach, Melissa M Toyos, Robert Smyth-Medina, Sidney L Weiss, Jodi I Luchs
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Clinical Ophthalmology (Auckland, N.Z.)
ISSN: 1177-5483
Popis: Tauber J, Schechter BA, Bacharach J, et al. Clin Ophthalmol.2018;12:1921–1929.On page 1927, “Safety and tolerability assessments” section,third paragraph, first sentence should read from “Fifteensubjects exited the study due to AEs: 5 subjects (3.3%) in theOTX-101 0.09% group, 4 subjects (2.6%) in the OTX-1010.09% group, and 6 subjects (3.9%) in the vehicle group.”to “Fifteen subjects exited the study due to AEs: 5 subjects(3.3%) in the OTX-101 0.09% group, 4 subjects (2.6%) inthe OTX-101 0.05% group, and 6 subjects (3.9%) in thevehicle group.”Read the original articlePrevious corrigendum has been published
Databáze: OpenAIRE